IBL HealthCare FY26 Results: Q4 Margin Compression, Cash Recovery

Verdict

IBL HealthCare Limited closed FY26 with a stronger balance sheet and a major improvement in cash conversion, but the final quarter was materially weaker at the operating level than the full-year headline suggests. Full-year revenue rose 6.6% and gross margin improved to 35.7%, yet the implied June quarter tells a different story: revenue still grew about 10.6% year on year, while cost of sales rose 25.5%, gross profit fell 12.8%, and gross margin compressed by roughly 8.2 percentage points. The result therefore looks less like a collapse in demand and more like a profitability test after the strong margin recovery achieved in FY25 and the first nine months of FY26.

The strongest part of the FY26 result is cash and working capital. Operating cash flow swung to positive Rs659.2 million from a Rs259.7 million outflow, year-end cash rose to Rs727.2 million, inventories and receivables fell, and short-term borrowings dropped to only Rs6.7 million. That materially lowers financing pressure. The main issue for the next cycle is whether IBL HealthCare can protect gross margin while continuing to grow revenue and sustain this much better cash discipline.

Results at a glance

Company: IBL HealthCare Limited
Ticker: IBLHL
Reporting period: year ended June 30, 2026; the quarter discussion uses an implied Q4 calculated from the official FY26 result less the officially reported nine months to March 31, 2026.
Reporting basis: company-level financial statements. The March 2026 interim statements are explicitly unaudited. The September 23, 2026 year-end PSX filing is the official Board-approved financial result and says the full annual report will be transmitted later; because that filing does not include the independent auditor's report, this article does not separately assert an audit opinion.

Alpha QoQ Score: 45.1
TTM Performance Score: 90.42
3Y Business Perf Score: 51.13
Sector Leadership Score: 31.6699

These four scores are AlphaGen model outputs, not company-reported figures.

Implied Q4 FY26: growth survived, margin did not

The implied June quarter is the most important part of the result because it shows a sharp change from the momentum visible at March. Q4 figures here are calculated by subtracting the official nine-month figures from the official full-year result, so they can absorb any year-end reclassification or adjustment and should not be read as separately published quarterly figures.

Revenue was approximately Rs1.302 billion, up 10.6% from about Rs1.178 billion in the comparable quarter. That is a respectable topline outcome. The problem is that cost of sales increased much faster, to roughly Rs902.2 million from Rs718.9 million, a 25.5% rise. Gross profit therefore declined 12.8% to about Rs400.1 million, and gross margin fell to 30.7% from 39.0%.

This is a meaningful reversal. At the nine-month stage, management had reported a 38% gross margin versus 31% a year earlier and attributed the improvement to a focus on profitable product portfolios, selective pricing and procurement efficiencies. The final quarter did not preserve that margin strength. Importantly, the year-end filing does not provide a Q4 driver bridge, so it would be inappropriate to claim that any single factor caused the compression.

There is, however, relevant macro context. IBL HealthCare described its portfolio in its FY25 annual report as import-led, while the State Bank of Pakistan warned in April 2026 that Middle East conflict had pushed global energy prices, freight charges and insurance premiums higher and disrupted supply chains. Those conditions are directionally consistent with pressure on imported-product economics, but this remains an inference rather than a company-confirmed explanation for Q4.

Operating profit pressure was broader than gross margin alone. Marketing and distribution expense in the implied Q4 fell around 6.0% year on year to Rs258.2 million, which offered some cushion, but administrative expense rose about 25.0% to Rs52.7 million. The FY26 statements also record an Rs11.3 million net impairment loss on financial assets that was not present in the nine-month statement, so it falls into the implied final-quarter bridge. On this basis, operating profit before finance cost fell to roughly Rs80.3 million from Rs136.0 million, and operating margin dropped to about 6.2% from 11.5%.

Finance cost was one clear positive. Implied Q4 finance cost fell about 10.9% to Rs10.3 million. For the full year it declined 28.8% to Rs42.9 million. Management had already linked the nine-month reduction to lower policy rates and improved cash management. The final quarter also saw a dramatic reduction in borrowings, although SBP raised its policy rate from 10.5% to 11.5% effective April 28, 2026. That makes IBL HealthCare's own balance-sheet deleveraging increasingly important to the finance-cost story.

Implied Q4 profit after tax was about Rs52.9 million versus Rs72.9 million, down 27.4%. Profit before income tax declined about 37.7% to Rs70.0 million. The tax charge fell more sharply, which softened the bottom-line decline. The prior-year quarter also contained an implied minimum-tax levy, while FY26 shows no levy line, so year-on-year pre-tax comparisons need to distinguish operating economics from tax and levy presentation.

What improved

The full-year picture is much better than Q4 in isolation. FY26 revenue increased 6.6% to Rs4.607 billion. Gross profit rose 13.7% to Rs1.645 billion, taking gross margin to 35.7% from 33.5%. That means the first nine months generated enough margin improvement to offset the late-year compression.

Finance costs fell to Rs42.9 million from Rs60.2 million. Profit before levy and income tax increased 6.4% to Rs401.3 million. Because FY26 had no separate levy charge versus Rs36.9 million in FY25, profit before income tax increased more strongly, to Rs401.3 million from Rs340.2 million. Profit after tax rose 5.8% to Rs220.4 million.

The balance sheet improved more decisively. Cash and bank balances rose to Rs727.2 million from Rs208.9 million. Inventories fell 30.4% to Rs884.2 million and trade and other receivables declined to Rs1.532 billion from Rs1.696 billion. Short-term borrowings fell to Rs6.7 million from Rs136.4 million, while current liabilities declined to Rs1.475 billion from Rs1.667 billion. Against current assets of Rs3.395 billion, the year-end current ratio improved to roughly 2.3x from about 2.0x.

The cash-flow statement confirms that these are not merely balance-sheet optics. Net cash generated from operating activities was Rs659.2 million in FY26 compared with a Rs259.7 million outflow in FY25. At March 31, 2026, operating cash flow had still been negative Rs389.8 million. The difference implies more than Rs1.0 billion of operating cash generation in the final quarter, although, as with the implied Q4 income statement, this subtraction can include year-end adjustments.

The balance-sheet movements explain much of that recovery. From March to June, inventories fell from Rs1.024 billion to Rs884.2 million and trade and other receivables fell from Rs2.313 billion to Rs1.532 billion, while cash jumped from Rs111.9 million to Rs727.2 million and short-term borrowings fell from Rs435.9 million to Rs6.7 million. Management had explicitly identified working-capital optimization as a priority in April; the year-end figures show substantial progress.

What weakened / needs attention

The central weakness is Q4 gross margin. A revenue increase accompanied by a much faster increase in cost of sales is not a healthy earnings mix unless management can show the pressure was temporary. The 30.7% implied Q4 gross margin is not only well below the comparable quarter's 39.0%, but also below the 38% margin reported for the first nine months.

Operating expenses also remain structurally heavier than before. For FY26, marketing and distribution expense rose 17.2% to Rs1.006 billion and administrative expense increased 34.9% to Rs194.3 million. As a result, despite higher full-year gross profit, operating profit increased only modestly to about Rs444.1 million and operating margin slipped to roughly 9.6% from about 10.1%.

Tax absorbed a larger share of earnings as well. FY26 income-tax expense increased to Rs180.9 million from Rs131.8 million. The absence of a separate levy line helped profit before income tax, but after tax, net margin was effectively flat at about 4.8%. In other words, the stronger gross margin and lower finance cost did not translate into a comparable expansion in net profitability.

Earnings quality: recurring versus exceptional

There is no large one-off gain in the FY26 profit and loss statement that artificially creates the reported profit. That is a positive. Revenue, gross profit and the bulk of operating earnings remain tied to the recurring distribution business.

Two items still deserve separation. First, FY26 includes an Rs11.3 million net impairment loss on financial assets, which is not a normal sales-margin driver and appears in the final-quarter bridge. Second, the year-on-year tax comparison is affected by the FY25 minimum-tax levy and by a higher FY26 income-tax charge. These items matter for reported PAT but do not explain the deterioration in Q4 gross economics.

The improvement in cash flow is economically valuable, but investors should also distinguish recurring operating cash generation from working-capital release. A large portion of the year-end cash improvement came alongside lower inventory and receivables. That is good execution, particularly after the March cash outflow, but the same magnitude of release cannot automatically repeat every year once working capital has normalized.

Historical pattern: recovery continued, but became less clean

FY25 was the recovery year. The company's audited FY25 report showed revenue rebounding 20% after FY24 weakness, gross margin recovering to 33.5% from 26.4%, and PAT rising to Rs208.4 million from only Rs7.6 million. Management attributed that turnaround to volume-led topline recovery, portfolio and mix improvement, calibrated pricing and tighter trade-term governance.

FY26 extended the recovery at the annual level: revenue, gross profit and PAT all increased, and gross margin rose further. But the pace changed. PAT growth slowed to 5.8%, full-year operating margin eased, and the final quarter produced a sharp gross-margin reversal. The business therefore exits FY26 in a stronger liquidity position but with a less comfortable operating-margin trajectory than the full-year gross-margin number alone suggests.

Peer and sector context

A directional peer check argues against calling IBL HealthCare's Q4 margin pressure purely company-specific or purely sector-wide. AGP Limited's PSX data show its June 2026 quarter sales at Rs3.747 billion versus Rs4.270 billion a year earlier and PAT at Rs318.9 million versus Rs626.9 million. That is a materially weaker quarter for another listed pharmaceutical player, although AGP's manufacturing and product mix differ from IBL HealthCare's distribution model.

At the same time, IBL HealthCare grew Q4 revenue while AGP's sales declined. The evidence therefore points to a mixed sector backdrop rather than a uniform demand shock. IBL HealthCare's specific issue was the conversion of revenue into gross profit.

Capital actions and shareholder distributions

The September 23 result announcement declared no cash dividend, bonus shares, right shares or other entitlement for FY26. During the year, however, the company completed the 15% bonus-share issuance that had been approved for FY25, increasing paid-up capital to Rs985.3 million from Rs856.7 million. The FY26 result accordingly presents prior-year EPS on a restated basis: FY26 EPS was Rs2.24 versus restated Rs2.11 for FY25.

What to monitor next

The first item is gross margin. A recovery toward the mid-30s would suggest Q4 was temporary; persistence around the low-30s would indicate the economics of procurement, pricing or product mix have changed.

Second is whether revenue growth remains positive without sacrificing margin. The company had previously highlighted profitable portfolio selection and selective pricing. The next result should show whether that discipline can coexist with growth after the Q4 cost-of-sales spike.

Third is working capital. The June balance sheet shows a major release of inventory and receivables and a near-elimination of short-term borrowing. The next cycle needs to show that cash conversion remains sound without constraining product availability or sales growth.

Fourth is operating-expense discipline. Marketing and administration grew faster than revenue for FY26. If gross margin remains under pressure, overhead growth becomes much more consequential.

Finally, the full FY26 annual report remains important. The September result filing provides the primary statements but states that the annual report will follow through PUCARS. That report should provide the detailed notes needed to explain Q4 cost of sales, the impairment charge, receivable composition, product-line mix and any other year-end adjustments.